Between the Lines Podcast: PET/CT-Guided Postprostatectomy Salvage Radiotherapy for Prostate Cancer

As part of the CancerNetwork® Between the Lines video series, Brian Helfand, MD, PhD, chief of the Division of Urology and the Ronald L. Chez Family and Richard Melman Family Endowed Chair at NorthShore University HealthSystem, and Steven Finkelstein, MD, FACRO, a radiation oncologist with Florida Cancer Affiliates, part of the US Oncology Network, in Panama City, Florida, examined the results and clinical implications of the EMPIRE-1 trial (NCT01666808) in prostate cancer.1 The trial compares 18F-fluciclovine PET/CT imaging versus conventional imaging to guide postprostatectomy salvage radiotherapy.

In the video series, Helfand and Finkelstein discussed the following:

• Phase 2/3 EMPIRE-1 Trial in Prostate Cancer
• Prostate Cancer: Clinical Implications From the EMPIRE-1 Trial

To watch more videos in the CancerNetwork® Between the Lines series, visit cancernetwork.com.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Reference

Jani AB, Schreibmann E, Goyal S, et al. 18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial. Lancet. 2021;397(10288):1895-1904. doi:10.1016/S0140-6736(21)00581-X